Form 4: Vor Biopharma Insider Sells 98,387 Shares

Reprogrammed Interchange LLC, a 10% owner and director, sold 98,387 shares of Vor Biopharma Inc. common stock across multiple transactions in early October 2025.

Summary

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc. (VOR), executed multiple sales of common stock on October 6 and 7, 2025.
• A total of 98,387 shares were sold through four separate transactions, all conducted under a Rule 10b5-1(c) pre-arranged trading plan.
• The sales occurred at weighted average prices ranging from $33.8369 to $37.7743 per share.
• Following these transactions, Reprogrammed Interchange LLC's direct beneficial ownership of Vor Biopharma common stock decreased to 1,498,921 shares.
• Reid Hoffman, who shares control over Reprogrammed Interchange LLC, disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a 10% owner and director. Although the sales were pre-planned under a 10b5-1 plan, which mitigates the immediate negative impact compared to opportunistic selling, it still represents a reduction in a key insider's stake.

Negatives

• A significant reduction in beneficial ownership by a 10% owner and director, Reprogrammed Interchange LLC, and indirectly Reid Hoffman, totaling 98,387 shares.

Risks

• The sale of a substantial number of shares by a significant insider could be perceived negatively by the market, potentially impacting investor confidence.
• While executed under a 10b5-1 plan, the reduction in insider stake may signal a lack of conviction or a strategic portfolio rebalancing, which could be interpreted as a bearish indicator.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Reid Hoffman disclaims beneficial ownership of the securities held by Reprogrammed Interchange LLC, except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing reports specific insider trading activity and does not provide broader industry context or trends.

Related Party Transactions

• The reported sales of common stock by Reprogrammed Interchange LLC, a 10% owner and entity associated with director Reid Hoffman, constitute related party transactions.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal of reduced confidence in the company's near-term prospects, potentially leading to downward pressure on the stock price.
• The transactions could influence market perception and investor sentiment towards Vor Biopharma Inc.

Key Dates

Recommendation

While the sales by Reprogrammed Interchange LLC were executed under a pre-arranged 10b5-1 plan, indicating they were not opportunistic, the reduction in a significant insider's stake (a 10% owner and director) is generally not a positive signal. Investors should hold and monitor for further developments, as this action could reflect a strategic portfolio adjustment rather than a direct negative outlook on the company, but it still removes a substantial block of shares from insider ownership.

Keywords

Vor Biopharma, VOR, Reprogrammed Interchange LLC, Reid Hoffman, insider trading, Form 4, stock sale, beneficial ownership, 10b5-1 plan